One-year outcomes of fixed-dosing Aflibercept therapy for pre treated and naive polypoidal choroidal vasculopathy patient

摘要

Polypoidal choroidal vasculopathy (PCV) is a type of age-related macular degeneration that can cause permanent vision loss. The purpose of this paper was to report the one-year outcomes of fixed-dosing aflibercept therapy for the treatment of PCV. This was a prospective, single-arm, interventional case series study of 25 PCV patients; 12 pre-treated and 13 treatment-na?ve patients. The patients were treated and monitored for 12?months. Each patient was administered with an aflibercept (2.0?mg) injection every month for the first 3 months (the loading phase), and thereafter, once every 2 months. At every follow-up visit, best-corrected visual acuity (BCVA) test, fundus examination, and optical coherence tomography for measuring the central subfield macular thickness (CSMT) were performed. Fluorescein and indocyanine green angiography were conducted at baseline and at 4 and 12?months. After 12?months of aflibercept therapy, the mean BCVA of the patients significantly improved from 65.48 letters at baseline to 69.91 letters (p=0.001), and the CSMT significantly decreased from 406.92 um at baseline to 276.12 um (p?0.001). Additionally, ten patients (40%) showed complete polyp regression. The treatment-na?ve patients showed a statistically significant improvement in BCVA from 66.58 letters at baseline to 76.36 letters at 12?months, and a significant decrease in CSMT, from 462 to 243 um. In the pre-treated group, there was no change in BCVA (64.46 letters), and the decrease in CSMT from 356.08 to 303.69 um was not statistically significant. The fixed-dosing aflibercept regimen is effective for treating patients with PCV and is more effective in treatment-na?ve patients than in pre-treated patients.